Cagrilintide is a long-acting amylin analogue that reduces appetite and slows gastric emptying, whilst retatrutide is a triple GLP-1, GIP, and glucagon receptor agonist designed to reduce appetite and increase energy expenditure
AOD-9604: Direct Lipolysis Theory AOD-9604 is a modified C-terminal fragment of human growth hormone, designed to isolate GH's fat-metabolizing properties: Lipolysis Activation: Theorized to stimulate fat breakdown through beta-3 adrenergic receptor pathways No IGF-1 Stimulation: Unlike full GH, AOD-9604 does not elevate insulin-like growth factor 1 Non-diabetogenic: Does not impair glucose metabolism or insulin sensitivity No Anabolic Effects: Does not promote muscle or organ growth Semaglutide: Central Regulation Theory Semaglutide achieves weight loss through systemic metabolic regulation: Hypothalamic Appetite Control: GLP-1 receptors in the brain reduce hunger and food-seeking behavior Gastric Emptying: Slowed stomach emptying promotes early satiety Insulin Optimization: Glucose-dependent insulin secretion improves metabolic efficiency Reward Pathway Modulation: Reduced hedonic eating and food reward responses The fundamental difference: AOD-9604 attempts to "burn" existing fat directly, while Semaglutide reduces caloric intake through appetite and satiety mechanisms, creating an energy deficit that leads to fat loss
Amphetamines Cannabinoids Cocaine Opiates Phencyclidine WHAT DRUGS ARE INCLUDED IN A 6 PANEL TEST
However, the group receiving both AOD9604 and HA showed the most favorable results, suggesting a potential synergistic interaction
To achieve optimal results, the B12 skinny shot should be combined with a healthy diet and regular exercise
Always refrigerate when not actively using
